A Randomised, Double-blind, Parallel-group, Placebo controlled, Induction Trial to Assess the Clinical Efficacy and Safety of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease.

Trial Profile

A Randomised, Double-blind, Parallel-group, Placebo controlled, Induction Trial to Assess the Clinical Efficacy and Safety of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs NN 8555 (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 21 Dec 2012 Planned End Date changed from 1 Jan 2014 to 1 Jun 2013 as reported by ClinicalTrials.gov record.
    • 19 Dec 2012 Results from an interim analysis have been reported in a Novo Nordisk media release.
    • 19 Dec 2012 Status changed from recruiting to discontinued as reported in a Novo Nordisk media release. This followed an interim futility analysis that indicated that the drug did to meet the pre-specified criteria for effect.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top